MedTrace Logo

Tongxinluo Improve High on Clopidogrel Platelet Reactivity Patients With Coronary Heart Disease

NCT01721590 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2015-12-23

No results posted yet for this study

Summary

Tongxinluo is a kind of Chinese patent drug,which could promote blood circulation.Recent reports suggested that tongxinluo's effectiveness in reducing the thrombin activity.In this prospective randomized study,all patients in control group will receive blank placebo ,all patients in test group will receive tongxinluo.All patients will be followed up for one year.

Conditions

Interventions

DRUG

Tongxinluo

Tongxinluo,3 capsules/time 3times/day for 1 year

DRUG

placebo

3 capsules/time，3times/day for 1 year

Sponsors & Collaborators

  • Han Yaling

    lead OTHER

Principal Investigators

  • Yaling Han, Dr · Shenyang Northern Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-05-31
Completion
2014-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01721590 on ClinicalTrials.gov